Clinical Trial Update: Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

View source ↗

Summary

A post-marketing surveillance study of Lorviqua (lorlatinib) in Korea for metastatic ALK-positive non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Non-small Cell Lung Cancer

Drugs mentioned

• Lorviqua (lorlatinib)

Snippet

Sponsor: Pfizer | Conditions: Metastatic ALK+ Non Small Cell Lung Cancer | Status: RECRUITING